3TR

3TR

Research Services

3TR has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434.

About us

Autoimmune, inflammatory and allergic diseases are common chronic diseases that significantly affect the wellbeing of millions of people around the globe and pose a substantial burden to healthcare systems. While different treatments are available, response and disease progression in individual patients remain unpredictable. Currently, still too little is known about the molecular basis underpinning these diseases. In order to be able to better predict treatment response and potentially identify novel biomarkers leading to improved patient management and personalised therapy, a deeper understanding of the cellular mechanisms driving disease development is urgently needed. In a never-before-seen effort 3TR sets out to fundamentally increase our knowledge of the molecular pathways and mechanisms linked to response and non-response to therapy in seven different immune-mediated, allergic and inflammatory diseases. It’s the largest immunology project funded by the Innovative Medicine Initiative (IMI) to date.

Industry
Research Services
Company size
201-500 employees
Founded
2019
Specialties
Biomarkers, Bioinformatics, Biotechnology, Molecular biology, Precision medicine, Immunotherapy, and Patient involvement

Updates

Affiliated pages

Similar pages